ELMSFORD, N.Y., June 16, 2020 /PRNewswire/ --
NanoVibronix, Inc., (NASDAQ: NAOV), a medical
device company that produces Surface Acoustic Wave (SAW) based
Ultrasonic Therapeutic Devices - the UroShield®, PainShield® and
WoundShield®, today announced that its newly introduced PainShield
PT 100 ultrasound therapy device has received the coveted Plus X
Award 2020 in the categories of high quality, design, ease of use
and functionality.
"Winning this award is a clear affirmation of the design,
quality and innovation behind our PainShield technology," said
Brian Murphy, CEO of NanoVibronix.
"Millions of people suffer from chronic pain and now more than
ever, clinicians and patients are looking for proven,
non-pharmaceutical alternatives for pain management that can be
administered in a variety of settings, especially the safety of a
patient's home. Access to effective home care is critically
important due to COVID-19 social distancing restrictions.
PainShield PT 100 ultrasound therapy provides non-opioid pain
therapy while maintaining social distancing at home and healthcare
facilities. The nomination by Medisana and quality seals awarded by
the panel at Plus X reinforce our confidence in the PainShield
product and our optimism for accelerating market acceptance."
The new private label PainShield PT 100 ultrasound therapy
device, which is sold directly and exclusively by Medisana outside
the United States, is a portable
therapeutic ultrasound device for the treatment of pain and soft
tissue injuries. It works with ultrasound at low intensity and low
frequency, thus improving local blood circulation, relieving local
inflammation and accelerating the healing of connective tissue. The
ultrasound therapy device is easy to use anywhere and anytime – at
home, at work, in a clinical setting or even while sleeping – with
comfortable, hands-free application. The Medisana PainShield PT 100
was designed specifically for the company to be sold throughout
their extensive international network. The ultrasound therapy
device enables the treatment of large body surfaces as well as
areas that are difficult to access without the use of ultrasound
gel.
About Plus X Award
The Plus X Award is the world's largest innovation award for
technology, sports and lifestyle. The award honors brands for the
leading edge in quality and innovation of their products. The Plus
X Award with its seven quality seals and selected specific awards
set the standard for the best products and are an unmistakable sign
for brand quality.
About Medisana
Medisana is one of the leading specialists on the home
healthcare market. For over 35 years, the German company has been
committed to people's health with the motto "Your health in good
hands." Medisana is a pioneer in the trend of mobile health
management and provides future-oriented products for modern
everyday life in an increasingly networked world. In the field of
massage, the Neuss-based company is the German market leader.
Medisana develops, markets, and sells products related to mobile
health, health monitoring, wellness, sports, personal care, therapy
and healthy homes to health-conscious consumers around the
world.
About NanoVibronix, Inc.
NanoVibronix, Inc. (NASDAQ: NAOV) is a medical device company
headquartered in Elmsford, New
York, with research and development in Nesher, Israel, focused on developing medical devices
utilizing its patented low intensity surface acoustic wave (SAW)
technology. The proprietary technology allows for the
creation of low-frequency ultrasound waves that can be utilized for
a variety of medical applications, including for disruption of
biofilms and bacterial colonization, as well as for pain relief.
The devices can be administered at home without the assistance of
medical professionals. The Company's primary products include
PainShield®, UroShield® and WoundShield®, all of which are portable
devices suitable for administration at home without assistance of
medical professionals. Additional information about NanoVibronix is
available at: www.nanovibronix.com.
Forward-looking Statements
This press release contains "forward-looking statements."
Such statements may be preceded by the words "intends," "may,"
"will," "plans," "expects," "anticipates," "projects," "predicts,"
"estimates," "aims," "believes," "hopes," "potential" or similar
words. Forward-looking statements are not guarantees of future
performance, are based on certain assumptions and are subject to
various known and unknown risks and uncertainties, many of which
are beyond the Company's control, and cannot be predicted or
quantified; consequently, actual results may differ materially from
those expressed or implied by such forward-looking statements. Such
risks and uncertainties include, without limitation, risks and
uncertainties associated with: (i) market acceptance of our
existing and new products or lengthy product delays in key markets;
(ii) negative or unreliable clinical trial results; (iii) inability
to secure regulatory approvals for the sale of our products,; (iv)
intense competition in the medical device industry from much
larger, multinational companies,; (v) product liability claims;
(vi) product malfunctions; (vii) our limited manufacturing
capabilities and reliance on subcontractor assistance; (viii)
insufficient or inadequate reimbursements by governmental and/or
other third party payers for our products; (ix) our ability to
successfully obtain and maintain intellectual property protection
covering our products; (x) legislative or regulatory reform
impacting the healthcare system in the U.S. or in foreign
jurisdictions; (xi) our reliance on single suppliers for certain
product components, (xii) the need to raise additional capital to
meet our future business requirements and obligations, given the
fact that such capital may not be available, or may be costly,
dilutive or difficult to obtain; and (xiii) our conducting business
in foreign jurisdictions exposing us to additional challenges, such
as, e.g., foreign currency exchange rate fluctuations, logistical
and communications challenges, the burden and cost of compliance
with foreign laws, and political and/or economic instabilities in
specific jurisdictions. More detailed information about the Company
and the risk factors that may affect the realization of forward
looking statements is set forth in the Company's filings with the
Securities and Exchange Commission (SEC), including the Company's
Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q.
Investors and security holders are urged to read these documents
free of charge on the SEC's web site at: http://www.sec.gov. The
Company assumes no obligation to publicly update or revise its
forward-looking statements as a result of new information, future
events, or otherwise.
View original
content:http://www.prnewswire.com/news-releases/nanovibronix-fulfills-its-first-private-label-partnership-with-medisana-and-receives-award-for-painshield-pt-100-quality-301077424.html
SOURCE NanoVibronix, Inc.